Egrifta Lyophilisate For Solution For Injection 2Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Egrifta: Lyophilisate for solution for injection (2mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

TESAMORELIN (TES a moe REL in) is used to reduce excess abdominal fat in HIV-infected patients.

In-Depth Information

EGRIFTA 2mg Powder for Injection

NDC: 440872011
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
HIV-associated Lipodystrophy

Storage Information
Reconstituted product should be used immediately. Discard unused portion
Store unreconstituted product in refrigerator (36 to 46 degrees F)
Store in original package until time of use
Protect from light
Discard product if it contains particulate matter, is cloudy, or discolored
Do not freeze
EGRIFTA 2mg Powder for Injection

Reported Side Effects for EGRIFTA 2mg Powder for Injection

Swelling Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
1.1%*
Severity: MODERATE
Onset: EARLY
Rapid Heart Rate Incidence:
1.1%*
Severity: MODERATE
Onset: EARLY
Night Sweats Incidence:
1.1-1.2%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
1.1%*
Severity: MILD
Onset: EARLY
Flushing Incidence:
1.2%*
Severity: MILD
Onset: RAPID
Hives Incidence:
1.2%*
Severity: MILD
Onset: RAPID
Itching Incidence:
1.2-2.4%*
Severity: MILD
Onset: RAPID
Muscle Pain Incidence:
1.2-5.5%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
1.2%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
1.3-1.6%*
Severity: MODERATE
Onset: EARLY
Wrist Nerve Pain Incidence:
1.5%*
Severity: MILD
Onset: DELAYED
Hypoesthesia Incidence:
1.6-4.2%*
Severity: MILD
Onset: DELAYED
Paresthesias Incidence:
1.6-4.8%*
Severity: MILD
Onset: DELAYED
Depression Incidence:
1.6-2.0%*
Severity: MODERATE
Onset: DELAYED
Bruise Incidence:
1.7%*
Severity: MODERATE
Onset: EARLY
Upset Stomach Incidence:
1.7%*
Severity: MILD
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
1.8%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
2.0-2.6%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
2.0-6.1%*
Severity: MODERATE
Onset: DELAYED
Loose Stools Incidence:
2.6-7.4%*
Severity: MILD
Onset: EARLY
Skin Irritation Incidence:
2.9%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
3.7%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
4.4%*
Severity: MILD
Onset: EARLY
Headache Incidence:
5.6%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
6.1-24.5%*
Severity: MILD
Onset: RAPID
Antibody Formation Incidence:
>10.0%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
13.3%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Egrifta

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5